Decreased Sex Hormone-Binding Globulin Indicated Worse Biometric, Lipid, Liver, and Renal Function Parameters in Women with Polycystic Ovary Syndrome

Xi Luo, Xin-Ming Yang, Wang-Yu Cai, Hui Chang, Hong-Li Ma, Yan Peng, Xiao-Ke Wu, Xi Luo, Xin-Ming Yang, Wang-Yu Cai, Hui Chang, Hong-Li Ma, Yan Peng, Xiao-Ke Wu

Abstract

Objective: To investigate the relationships between sex hormone-binding globulin (SHBG) and comprehensive metabolic parameters including biometric, glycemic, lipid, liver, and renal functions of women with polycystic ovary syndrome (PCOS). Study Design and Methods. A total of 1000 women diagnosed as PCOS by modified Rotterdam criteria were enrolled in a randomized controlled trial. SHBG and comprehensive metabolic parameters were measured at the baseline visit. Metabolic parameters included biometric parameters, glucose and lipid panels, and liver and renal function parameters. An independent t-test and linear regression were performed to investigate the associations between SHBG and metabolic parameters. Logistic regression was used to detect the relationship between SHBG and the presence of metabolic syndrome.

Results: In comparative analyses, PCOS women with lower SHBG levels had higher body mass index, waist circumference, insulin, homeostatic model assessment-insulin resistance (HOMA-IR) index, systolic and diastolic blood pressure, triglycerides, apolipoprotein B (APOB), low-density lipoprotein (LDL), aspartate transferase (AST), alanine transferase (ALT), and blood urea nitrogen (BUN), but lower high-density lipoprotein (HDL) and apolipoprotein A1 (APOA1). In linear regression, SHBG was inversely associated with waist circumference, systolic blood pressure, triglyceride, LDL, APOB, ALT, AST, and BUN but positively associated with HDL and APOA1 after adjusting the BMI. In logistic regression, SHBG is a protective predictor for metabolic syndrome (odds ratio = 0.96; 95% confidence interval: 0.95-0.97). The area under the receiver-operator characteristic curve is 0.732 with a 95% confidence interval of 0.695-0.770. SHBG <26.75 mmol/L is the cutoff point with the best Youden index, which has a sensitivity of 0.656 and specificity of 0.698.

Conclusions: Lower SHBG was associated with worsening biometric, lipid, liver, and renal functions but not glycemic parameters among women with PCOS. SHBG can be used as a tool to screen metabolic syndrome. This trial is registered with NCT01573858 and ChiCTR-TRC-12002081.

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Copyright © 2020 Xi Luo et al.

Figures

Figure 1
Figure 1
Receiver-operating characteristic curve of SHBG for metabolic syndrome.

References

    1. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS) Human Reproduction. 2004;19(1):41–47. doi: 10.1093/humrep/deh098.
    1. Gilbert E. W., Tay C. T., Hiam D. S., Teede H. J., Moran L. J. Comorbidities and complications of polycystic ovary syndrome: an overview of systematic reviews. Clinical Endocrinology. 2018;89(6):683–699. doi: 10.1111/cen.13828.
    1. Behboudi-Gandevani S., Amiri M., Bidhendi Yarandi R., et al. The risk of metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Clinical Endocrinology. 2018;88(2):169–184. doi: 10.1111/cen.13477.
    1. Rocha A. L. L., Faria L. C., Guimarães T. C. M., et al. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: systematic review and meta-analysis. Journal of Endocrinological Investigation. 2017;40(12):1279–1288. doi: 10.1007/s40618-017-0708-9.
    1. Targher G., Rossini M., Lonardo A. Evidence that non-alcoholic fatty liver disease and polycystic ovary syndrome are associated by necessity rather than chance: a novel hepato-ovarian axis? Endocrine. 2016;51(2):211–221. doi: 10.1007/s12020-015-0640-8.
    1. Spoto B., Pisano A., Zoccali C. Insulin resistance in chronic kidney disease: a systematic review. American Journal of Physiology-Renal Physiology. 2016;311(6):F1087–F1108. doi: 10.1152/ajprenal.00340.2016.
    1. Lakkis JI, Weir MR. Obesity and kidney disease. Progress in cardiovascular diseases. 2018;61(2):157–167. doi: 10.1016/j.pcad.2018.07.005.
    1. Daka B., Rosen T., Jansson P. A., Larsson C. A., Råstam L., Lindblad U. Low sex hormone-binding globulin is associated with hypertension: a cross-sectional study in a Swedish population. BMC Cardiovascular Disorders. 2013;13(1):p. 30. doi: 10.1186/1471-2261-13-30.
    1. Ding E. L., Song Y., Manson J. E., et al. Sex hormone-binding globulin and risk of type 2 diabetes in women and men. New England Journal of Medicine. 2009;361(12):1152–1163. doi: 10.1056/nejmoa0804381.
    1. Li C., Ford E. S., Li B., Giles W. H., Liu S. Association of testosterone and sex hormone-binding globulin with metabolic syndrome and insulin resistance in men. Diabetes Care. 2010;33(7):1618–1624. doi: 10.2337/dc09-1788.
    1. Seo I.-H., Lee H.-B., Kim S., Lee Y.-J., Jung D.-H. Inverse relationship between hepatic steatosis and alanine aminotransferase with sex hormone-binding globulin in men. Yonsei Medical Journal. 2017;58(4):731–736. doi: 10.3349/ymj.2017.58.4.731.
    1. Deswal R., Yadav A., Dang A. S. Sex hormone binding globulin - an important biomarker for predicting PCOS risk: a systematic review and meta-analysis. Systems Biology in Reproductive Medicine. 2018;64(1):12–24. doi: 10.1080/19396368.2017.1410591.
    1. Moran L. J., Teede H. J., Noakes M., Clifton P. M., Norman R. J., Wittert G. A. Sex hormone binding globulin, but not testosterone, is associated with the metabolic syndrome in overweight and obese women with polycystic ovary syndrome. Journal of endocrinological investigation. 2013;36(11):1004–10.
    1. Wu X. K., Stener-Victorin E., Kuang H. Y., et al. Effect of acupuncture and clomiphene in Chinese women with polycystic ovary syndrome: a randomized clinical trial. Journal of the American Medical Association (JAMA) 2017;317(24):2502–2514.
    1. Chen Z. Diagnosis and treatment of polycystic ovary syndrome: standard and guideline of ministry of health of People’s Republic of China. Zhonghua Fu Chan Ke Za Zhi. 2018;53(1):2–6.
    1. Li R., Qiao J., Yang D., et al. Epidemiology of hirsutism among women of reproductive age in the community: a simplified scoring system. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2012;163(2):165–169. doi: 10.1016/j.ejogrb.2012.03.023.
    1. Harrell F. E., Lee K. L., Mark D. B. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Statistics in Medicine. 1996;15(4):361–387.
    1. Steyerberg E. W., Eijkemans M. J. C., Harrell F. E., Habbema J. D. F. Prognostic Modeling with Logistic Regression Analysis. Medical Decision Making. 2001;21(1):45–56. doi: 10.1177/0272989x0102100106.
    1. Hanley J. A., McNeil B. J. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143(1):29–36. doi: 10.1148/radiology.143.1.7063747.
    1. Goverde A. J., van Koert A. J. B., Eijkemans M. J., et al. Indicators for metabolic disturbances in anovulatory women with polycystic ovary syndrome diagnosed according to the Rotterdam consensus criteria. Human Reproduction. 2008;24(3):710–717. doi: 10.1093/humrep/den433.
    1. Zhang B., Wang J., Shen S., et al. Association of androgen excess with glucose intolerance in women with polycystic ovary syndrome. Biomed Research International. 2018;2018:6. doi: 10.1155/2018/6869705.6869705
    1. Mishra J. S., More A. S., Kumar S. Elevated androgen levels induce hyperinsulinemia through increase in Ins1 transcription in pancreatic beta cells in female rats†. Biology of Reproduction. 2018;98(4):520–531. doi: 10.1093/biolre/ioy017.
    1. Wang H., Wang X., Zhu Y., Chen F., Sun Y., Han X. Increased androgen levels in rats impair glucose-stimulated insulin secretion through disruption of pancreatic beta cell mitochondrial function. The Journal of Steroid Biochemistry and Molecular Biology. 2015;154:254–266. doi: 10.1016/j.jsbmb.2015.09.003.
    1. Nestler J. E., Jakubowicz D. J., Falcon de Vargas A., Brik C., Quintero N., Medina F. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovary syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system1. The Journal of Clinical Endocrinology & Metabolism. 1998;83(6):2001–2005. doi: 10.1210/jcem.83.6.4886.
    1. Feng C., Jin Z., Sun L., et al. Endogenous SHBG levels correlate with that of glucose transporters in insulin resistance model cells. Molecular Biology Reports. 2019;46(5):4953–4965. doi: 10.1007/s11033-019-04946-w.
    1. Feng C., Jin Z., Chi X., et al. SHBG expression is correlated with PI3K/AKT pathway activity in a cellular model of human insulin resistance. Gynecological Endocrinology. 2018;34(7):567–573. doi: 10.1080/09513590.2017.1411474.
    1. Perry J. R., Weedon M. N., Langenberg C., et al. Genetic evidence that raised sex hormone binding globulin (SHBG) levels reduce the risk of type 2 diabetes. Human Molecular Genetics. 2010;19(3):535–544.
    1. Veltman-Verhulst S. M., van Haeften T. W., Eijkemans M. J. C., et al. Sex hormone-binding globulin concentrations before conception as a predictor for gestational diabetes in women with polycystic ovary syndrome. Human Reproduction. 2010;25(12):3123–3128. doi: 10.1093/humrep/deq272.
    1. Wang Q., Kangas A. J., Soininen P., et al. Sex hormone-binding globulin associations with circulating lipids and metabolites and the risk for type 2 diabetes: observational and causal effect estimates. International Journal of Epidemiology. 2015;44(2):623–637. doi: 10.1093/ije/dyv093.
    1. Desmeules A. Post-heparin lipolytic enzyme activities, sex hormones and sex hormone-binding globulin (SHBG) in men and women: the HERITAGE Family Study. Atherosclerosis. 2003;171(2):343–350. doi: 10.1016/j.atherosclerosis.2003.08.018.
    1. Cai W.-Y., Gao J.-S., Luo X., et al. Effects of metabolic abnormalities, hyperandrogenemia and clomiphene on liver function parameters among Chinese women with polycystic ovary syndrome: results from a randomized controlled trial. Journal of Endocrinological Investigation. 2019;42(5):549–555. doi: 10.1007/s40618-018-0953-6.
    1. Chen M.-J., Chiu H.-M., Chen C.-L., Yang W.-S., Yang Y.-S., Ho H.-N. Hyperandrogenemia is independently associated with elevated alanine aminotransferase activity in young women with polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism. 2010;95(7):3332–3341. doi: 10.1210/jc.2009-2698.
    1. Reckelhoff J. F., Yanes L. L., Iliescu R., Fortepiani L. A., Granger J. P. Testosterone supplementation in aging men and women: possible impact on cardiovascular-renal disease. American Journal of Physiology-Renal Physiology. 2005;289(5):F941–F948. doi: 10.1152/ajprenal.00034.2005.
    1. Rosner W., Hryb D. J., Kahn S. M., Nakhla A. M., Romas N. A. Interactions of sex hormone-binding globulin with target cells. Molecular and Cellular Endocrinology. 2010;316(1):79–85. doi: 10.1016/j.mce.2009.08.009.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する